Ongoing research developments in cardio-oncology

• Authors: Susan Dent , Olexiy Aseyev , Daniel Lenihan
• Languages of publication: EN

Discipline

• MEDICINE: MEDICINE

• Journal: OncoReview
• Year: 2016
• Volume: 6
• Issue: 1
• Pages: A27-28

Contributors

author

Susan Dent

• The Ottawa Hospital Cancer Centre, University of Ottawa, Ontario, Canada,

author

Olexiy Aseyev

• The Ottawa Hospital Cancer Centre, University of Ottawa, Ontario, Canada

author

Daniel Lenihan

• Vanderbilt University, Division of Cardiology, United States

References

• 1. Amiri-Kordestani L, Beaver JA, Cortazar P. Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives. Oncology (Williston Park) 2015; 29(11): 843-844, 846.
• 2. Amiri-Kordestani L, Wedam S, Zhang L et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014; 20(21): 5359-5364.
• 3. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice. Fed Requist 2010; 75(44): 10487-10488.
• 4. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013; 63(4): 249-279.
• 5. Herndon TM, Deisseroth A, Kaminskas E et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19(17): 4559-4563.
• 6. Sysa-Shah P, Tocchetti CG, Gupta M et al. Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. Cardiovasc Res 2015; Dec 21. pii: cvv274 [epub ahead of print].

• Document Type: minireview